市场调查报告书

癌检验/筛检市场预测:影像·生物标记·放射线·其他

Cancer Testing/Screening Market - Forecast (2020 - 2025)

出版商 IndustryARC 商品编码 622599
出版日期 内容资讯 英文 112 Pages
商品交期: 2-3个工作天内
价格
癌检验/筛检市场预测:影像·生物标记·放射线·其他 Cancer Testing/Screening Market - Forecast (2020 - 2025)
出版日期: 2020年03月11日内容资讯: 英文 112 Pages
简介

本报告提供全球癌检验/筛检的市场调查,提供市场定义和概要,主要经营者与市场占有率,市场的各种影响因素分析,价值链,市场机会·市场生命周期分析,癌区分·技术·治疗区分·地区/各主要国家趋势与市场规模的变化与预测,并汇整主要企业简介等资讯。

第1章 市场概要

第2章 摘要整理

第3章 市场环境

  • 市场占有率分析
  • 竞争经营者分析
    • 产品基准
    • 终端用户的简介
    • 前五名公司的财务分析

第4章 市场影响因素

  • 成长推进因素
  • 阻碍成长要素·课题
  • 产业的魅力

第5章 策略性市场分析

  • 价值链分析
  • 价格分析
  • 市场机会分析
  • 产品生命周期
  • 供应商·流通经销商

第6章 市场分析·预测:各类型

  • 简介
  • 肺癌
  • 血液癌
  • 骨癌
  • 腹部的癌
  • 眼癌
  • 口腔癌
  • 乳癌
  • 其他

第7章 市场分析·预测:各技术

  • 简介
  • 影像
  • 生物标记
  • 内视镜检验
  • 放射线
  • 其他

第8章 市场分析·预测:不同治疗

  • 简介
  • 外科手术
  • 放射线
  • 荷尔蒙疗法
  • 化疗
  • 基因治疗
  • 其他

第9章 市场分析·预测:各阶段

  • TNM分类
  • 阶段0-4
  • 预后因素
  • 其他

第10章 市场分析·预测:男女

  • 男性
  • 女性

第11章 市场分析·预测:各地区

  • 简介
  • 南北美洲
    • 美国
    • 加拿大
    • 墨西哥
    • 巴西
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 其他
  • 亚太地区
    • 中国
    • 韩国
    • 澳洲&纽西兰
    • 日本
    • 印度
    • 其他
  • 其他地区
    • 中东·非洲

第12章 市场熵

  • 新产品的开发
  • 产品的投入·JV·M&A

第13章 企业简介

  • Dias Orin S.P.A
  • Immunodiagnostic Systems Holdings Plc
  • Epigenomics Ag
  • Techlab, Inc.
  • Genextropy, Inc.
  • Lifecode
  • Genclis Sa
  • Target Discovery
  • Positive Bioscience
  • Celdara Medical, Llc

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: HCR 0078

Cancer Testing/Screening Market Overview:

According to the findings by WHO, the global mortality rate due to cancer in 2018 surged to 9.6 million. The same study states that up to an astonishing 50% of cancer cases could have been prevented with effective and inexpensive programmes in initial diagnosis, screening, treatment, and palliative care. With the annual economic burden of cancer well-exceeding US$1.16 trillion, the demand for medical facilities to detect and control this intricate disease at the earliest is surfacing the global healthcare forum.[1] Owing to this demand, the global cancer testing market or cancer screening market size is estimated to be $123 billion-$133 billion as of 2018 and is growing at a global CAGR of 4.5%-5.5% during the forecast period 2019-2025.

Cancer Testing Market Outlook:

Cancer testing or screening plays an important role in the detection of various types of cancer before the appearance of symptoms. The main aim of cancer testing is to reduce the number of deaths caused by cancer. Early diagnosis can lead to better treatment and a greater lifespan. Some of the cancer prevention testing-screening tests include various medical imaging tests, screening mammography, endoscopy tests, and biopsy tests.

After an acute analysis of the regional market segments, the Americas is figured to be the leading region, encapsulating nearly 50%-55% of the global cancer testing market demand. The sheer affluence can be explained by the fact that alone in the United States, the number of cancer cases registered in 2018 was estimated to be 1,735,350 (1.7 million).[2] Similarly, the Canadian Cancer Society states that about 1 in 2 Canadians will develop cancer in their lifetimes and 1 in 4 will die of the disease.[3] Cancer screening-testing being an expensive medical procedure has found the scope of application in high-income countries only as of right now. However, government support and indigenous technologies from countries such China, India, and Japan is helping the market penetration and mass commercialization. The majority of low-income economies with inaccessible diagnosis and treatment facilities stands out as potential spots to be capitalized upon by the cancer-screening testing market players.

Cancer Screening Market Growth Drivers and Trends:

'Liquid biopsy' is one of the latest technology emerging in the market which would help in early detection of various cancers by scanning for DNA fragments which are shed by tumor cells. Companies such SRBI healthcare, GRAIL Inc., and others are raising funds for early diagnosis of cancer.

In recent years, Next Generation Sequencing (NGS) is being widely used for the detection of various types of cancer. NGS allows simultaneous sequencing of targeted genomic areas in multiple samples to detect mutations. The main advantage of this method is the need of low amount of DNA or RNA.

Swiss startup SOPHiA Genetics has used Artificial Intelligence (AI) that takes raw genome data and studies the molecular profile of a person's cancer to find more personalized treatment options. This technology helps the doctors to understand the cause of cancer and what best treatment can be suggested for the molecular events that are taking place in the body. It is also predicted that AI would be the future of cancer diagnostics.

Research and campaigns run by several organization regarding timely screening and cancer diagnosis are also disrupting the cancer-testing marketplace and progressing it towards broader commercialization. For example- Centers for Disease Control and Prevention campaign 'Screen for Life'. American Cancer Society in 2017 invested $145 million in cancer research, $129 million in prevention information, and $80 million in detection.

Cancer Testing Market

Cancer Screening Market Players Perspective:

Some of the major key players operating in this technological novel and advanced healthcare landscape are Dias Orin S.P.A, Epigenetics Ag, Techlab, Genextropy Inc., M Genomics Ltd, 20/20 GeneSystems, Inc., AB SCIEX, Abbott Laboratories, Abcodia Ltd., and Abingdon Health Ltd.

Cancer Testing Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the cancer testing/screening market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnosis in cancer testing/screening market and their specific advantages.

Cancer Testing/Screening Market Report: Industry Coverage

By Cancer Type: Lung, Blood, Bone, Others

By Technique: Imaging, Endoscopy, Molecular & Genomics Testing

By Stage: TNM, Prognostic Factors, Others

The Cancer Testing/Screening Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

1. Cancer Testing/Screening Market - Overview

  • 1.1. Definitions and Scope

2. Cancer Testing/Screening Market - Executive summary

  • 2.1. Market Revenue, Market Size and Key Trends by Company
  • 2.2. Key Trends by type of Application
  • 2.3. Key Trends segmented by Geography

3. Cancer Testing/Screening Market

  • 3.1. Comparative analysis
    • 3.1.1. Product Benchmarking - Top 10 companies
    • 3.1.2. Top 5 Financials Analysis
    • 3.1.3. Market Value split by Top 10 companies
    • 3.1.4. Patent Analysis - Top 10 companies
    • 3.1.5. Pricing Analysis

4. Cancer Testing/Screening Market Forces

  • 4.1. Drivers
  • 4.2. Constraints
  • 4.3. Challenges
  • 4.4. Porters five force model
    • 4.4.1. Bargaining power of suppliers
    • 4.4.2. Bargaining powers of customers
    • 4.4.3. Threat of new entrants
    • 4.4.4. Rivalry among existing players
    • 4.4.5. Threat of substitutes

5. Cancer Testing/Screening Market -Strategic analysis

  • 5.1. Value chain analysis
  • 5.2. Opportunities analysis
  • 5.3. Product life cycle
  • 5.4. Suppliers and distributors Market Share

6. Cancer Testing/Screening Market - By Type (Market Size -$Million / $Billion)

  • 6.1. Market Size and Market Share Analysis
  • 6.2. Application Revenue and Trend Research
  • 6.3. Product Segment Analysis
    • 6.3.1. Introduction
    • 6.3.2. Lung Cancer
    • 6.3.3. Blood Cancer
    • 6.3.4. Bone Cancer
    • 6.3.5. Gall Bladder Cancer
    • 6.3.6. Testicular Cancer
    • 6.3.7. Thyroid Cancer
    • 6.3.8. Kidney Cancer
    • 6.3.9. Liver Cancer
    • 6.3.10. Pancreatic Cancer
    • 6.3.11. Brain Cancer
    • 6.3.12. Abdominal Cancer
    • 6.3.13. Eye Cancer
    • 6.3.14. Mouth Cancer
    • 6.3.15. Breast Cancer
    • 6.3.16. Cervix Cancer
    • 6.3.17. Ovarian Cancer
    • 6.3.16. Others

7. Cancer Testing/Screening Market - By Technique (Market Size -$Million / $Billion)

  • 7.1. Introduction
  • 7.2. Imaging Techniques
    • 7.2.1. CT scan
    • 7.2.2. MRI
    • 7.2.3. X-ray
    • 7.2.4. Nuclear
    • 7.2.5. Ultrasound
    • 7.2.6. Mammography
    • 7.2.7. Others
  • 7.3. Endoscopy procedure
    • 7.3.1. Colonoscopy
    • 7.3.2. Sigmoidoscopy
    • 7.3.3. Others
  • 7.4. Biopsy and cytology tests
    • 7.4.1. Needle biopsy
    • 7.4.2. CT-guided biopsy
    • 7.4.3. Ultrasound-guided biopsy
    • 7.4.4. Bone biopsy
    • 7.4.5.Bone marrow biopsy
    • 7.4.6.Liver biopsy
    • 7.4.7.Kidney biopsy
    • 7.4.8. Aspiration biopsy
    • 7.4.9. Prostate biopsy
    • 7.4.10 Skin biopsy
    • 7.4.11 Surgical biopsy
    • 7.4.12 Others
  • 7.5. Genomic and Molecular tests
    • 7.5.1. Next Generation Sequencing (NGS)
    • 7.5.2. RT- PCR
    • 7.5.3. icroarray techniques
    • 7.5.4. Biomarker testing
    • 7.5.5. Others

8. Cancer Testing/Screening Market - By Stage (Market Size -$Million / $Billion)

  • 8.1. TNM Stages
  • 8.2. Stages 0,1,2,3,4
  • 8.3. Prognostic Factors
  • 8.4. Other Staging Systems

9. Cancer Testing/Screening Market - By Gender (Market Size -$Million / $Billion)

  • 9.1. Men
    • 9.1.1. New Born
    • 9.1.2. Infant
    • 9.1.3. Child
    • 9.1.4. Adolescent
    • 9.1.5. Adults
    • 9.1.6. Seniors
  • 9.2. Women
    • 9.2.1. New Born
    • 9.2.2. Infant
    • 9.2.3. Child
    • 9.2.4. Adolescent
    • 9.2.5. Adults
    • 9.2.6. Seniors

10. Cancer Testing/Screening - By Geography (Market Size -$Million / $Billion)

  • 10.1. Cancer Testing/Screening Market - North America Segment Research
  • 10.2. North America Market Research (Million / $Billion)
    • 10.2.1. Segment type Size and Market Size Analysis
    • 10.2.2. Revenue and Trends
    • 10.2.3. Application Revenue and Trends by type of Application
    • 10.2.4. Company Revenue and Product Analysis
    • 10.2.5. North America Product type and Application Market Size
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
      • 10.2.5.4. Rest of North America
  • 10.3. Cancer Testing/Screening - South America Segment Research
  • 10.4. South America Market Research (Market Size -$Million / $Billion)
    • 10.4.1. Segment type Size and Market Size Analysis
    • 10.4.2. Revenue and Trends
    • 10.4.3. Application Revenue and Trends by type of Application
    • 10.4.4. Company Revenue and Product Analysis
    • 10.4.5. South America Product type and Application Market Size
      • 10.4.5.1. Brazil
      • 10.4.5.2. Venezuela
      • 10.4.5.3. Argentina
      • 10.4.5.4. Ecuador
      • 10.4.5.5. Peru
      • 10.4.5.6. Colombia
      • 10.4.5.7. Costa Rica
      • 10.4.5.8. Rest of South America
  • 10.5. Cancer Testing/Screening - Europe Segment Research
  • 10.6. Europe Market Research (Market Size -$Million / $Billion)
    • 10.6.1. Segment type Size and Market Size Analysis
    • 10.6.2. Revenue and Trends
    • 10.6.3. Application Revenue and Trends by type of Application
    • 10.6.4. Company Revenue and Product Analysis
    • 10.6.5. Europe Segment Product type and Application Market Size
      • 10.6.5.1. U.K
      • 10.6.5.2. Germany
      • 10.6.5.3. Italy
      • 10.6.5.4. France
      • 10.6.5.5. Netherlands
      • 10.6.5.6. Belgium
      • 10.6.5.7. Spain
      • 10.6.5.8. Denmark
      • 10.6.5.9. Rest of Europe
  • 10.7. Cancer Testing/Screening - APAC Segment Research
  • 10.8. APAC Market Research (Market Size -$Million / $Billion)
    • 10.8.1. Segment type Size and Market Size Analysis
    • 10.8.2. Revenue and Trends
    • 10.8.3. Application Revenue and Trends by type of Application
    • 10.8.4. Company Revenue and Product Analysis
    • 10.8.5. APAC Segment - Product type and Application Market Size
      • 10.8.5.1. China
      • 10.8.5.2. Australia
      • 10.8.5.3. Japan
      • 10.8.5.4. South Korea
      • 10.8.5.5. India
      • 10.8.5.6. Taiwan
      • 10.8.5.7. Malaysia

11. Cancer Testing/Screening Market - Entropy

  • 11.1. New product launches
  • 11.2. M&A's, collaborations, JVs and partnerships

12. Cancer Testing/Screening Market Company Analysis

  • 12.1. Market Share, Company Revenue, Products, M&A, Developments
  • 12.2. Dias Orin S.P.A
  • 12.3. Epigenetics Ag
  • 12.4. Techlab
  • 12.5. Positive Bioscience
  • 12.6. Genextropy Inc.
  • 12.7. M Genomics Ltd
  • 12.8. 20/20 GeneSystems, Inc.
  • 12.9. AB SCIEX
  • 12.10. Abbott Laboratories
  • 12.11. Abcodia Ltd.
  • 12.12. Company 11
  • 12.13. Company 12
  • 12.14. Company 13 and more

"*Financials would be provided on a best efforts basis for private companies"

13. Cancer Testing/Screening Market -Appendix

  • 13.1. Abbreviations
  • 13.2. Sources